Testing OCT-980 tablets in people with a genetic form of retinitis pigmentosa
Tests OCT-980 in healthy adults and adults with inherited retinitis pigmentosa.
Plain-language title generated from the registry record
Registry title: A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Key facts
- Where
- Dallas and Portland, United StatesSee the 2 sites
- Phase
- Phase 1/2
Where in United States
- Retina Foundation of the SouthwestDallas, United StatesTaking people
- Casey Eye InstitutePortland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Octant, Inc.
- Trial code
- NCT07408232
- Record updated
- 24 September 2026
- Original description
This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.Read full original descriptionShow less
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of OCT-980 in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa
This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.
Phase 1b/2 is active. Inclusion; Phase 1b/2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Inclusion:; Participants must have a diagnosis of Rhodopsin-associated, autosomal dominant Retinitis Pigmentosa confirmed by a genetic test that is implemented in accordance with the relevant national requirements; Male or female greater than or equal to age 18 (inclusive) at the time of signing the informed consent form; Have a body weight >50kg, with a body mass index (BMI) from 18.0 to 35.0 kg/m\^2 (inclusive) at screening; Best Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) > 55; Other than their diagnosis of RHO-adRP, be in good general health, as determined by the Investigator; Have sufficient venous access to allow blood sampling for pharmacokinetic analysis and safety laboratory samples; Phase 1b/2 (Multiple Ascending Dose Escalation in RHO-adRP Patients) Exclusion:; Females who are pregnant or breastfeeding; Evidence of any other significant ocular (other than RHO-adRP) and non-ocular disease/ disorder; Lifetime history of ocular surgery; Any prior or current ophthalmologic gene therapy; Has a history of major surgery, severe trauma, or bone fracture within 12 weeks before the first dose of the investigational product or planned surgery within 4 weeks after the end of the study.